Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03336645
Other study ID # SHP615-301
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 23, 2017
Est. completion date August 19, 2019

Study information

Verified date June 2020
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 19, 2019
Est. primary completion date August 19, 2019
Accepts healthy volunteers No
Gender All
Age group 3 Months to 216 Months
Eligibility Inclusion Criteria:

- Male and female participants whose corrected gestational age is greater than or equal to (>=) 52 weeks (gestational weeks plus the number of weeks after birth) and less than (<) 18 years (and weight greater than [>] 5 kilogram [kg]), at the time of investigational product administration. If the participant's exact age is not known, the participant should be excluded.

- Parent, guardian, or legally authorized representative (LAR) of the child provides informed consent (and assent, when applicable per Shire policy and country regulations) to participate in the study prior to participation in any protocol specific procedures. The participant may be prescreened by the investigator in their clinical practice and the parent, guardian, or LAR may sign informed consent before the participant presents to the healthcare setting for treatment of the seizure.

- Participant with generalized tonic-clonic SE with seizures accompanied by loss of consciousness with any of the following characteristics persistent at the time of study drug administration:

1. Currently presenting with seizure (convulsive) activity and 3 or more convulsions within the preceding hour

2. Currently presenting with seizure (convulsive) and 2 or more convulsions in succession without recovery of consciousness

3. Currently presenting with a single seizure (convulsive) lasting >=5 mins

Exclusion Criteria:

- Female participants who are pregnant, suspected to be pregnant, or nursing.

- Subjects with major trauma, not necessarily restricted to the head, as the cause of the seizure.

- Subjects with seizures due to illegal drug or acute alcoholic intoxication.

- Subjects with known or suspected recurrent seizures due to illegal drug or alcohol withdrawal.

- Subjects with history of seizures of psychogenic origin.

- Subjects with seizures due to severe encephalitis or meningitis, as determined by the PI

- Subjects with known history of hypersensitivities, non-responsiveness or contraindications to benzodiazepines (ie, clinically significant respiratory depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea, glaucoma with closed angle, use of concomitant drugs determined by the investigator to have a contraindication to the use of benzodiazepines.)

- Subjects with a known history of benzodiazepine abuse.

- Subjects who, in the judgment of the healthcare provider, have not responded to previous administrations of midazolam systemic therapies, including Midafresa and/or Dormicum.

- Subjects who need emergent surgical intervention and general anesthesia/intubation.

- Subjects with significant hypotension and cardiac dysrhythmia (example [eg], atrioventricular [AV] block of second or third degree, VT [ventricular tachycardia]).

- Subjects who have been receiving human immunodeficiency virus (HIV) protease inhibitors or HIV reverse transcriptase inhibitors.

- Subjects with current hypoglycemia (glucose <60 milligram per deciliter [mg/dL]) upon presentation at the hospital or healthcare setting.

- Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the healthcare provider.

- Subjects have used an investigational product or been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.

- Subjects has received antiseizure medication prior to arrival in the healthcare setting.

- Subjects has prior placement of a vagus nerve stimulator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SHP615
SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).

Locations

Country Name City State
Japan Fukuoka Children's Hospital(NW) Fukuoka
Japan Gifu Prefectural General Medical Center Gifu Gifu Prefecture
Japan NHO Hokkaido Medical Center Hokkaido
Japan Yamanashi Prefectural Central Hospital Kofu Fujimi
Japan Kumamoto Saishunso National Hospital Kumamoto
Japan NHO Nagasaki Medical Center Nagasaki
Japan NHO Nishi Niigata Chuo National Hospital Niigata
Japan Aichi Children's Health and Medical Center(NW) Obu
Japan NHO Minami-Okayama Medical Center Okayama Okayama Prefecture
Japan Okayama University Hospital Okayama
Japan Nakano Children's Hospital Osaka
Japan Osaka Women's and Children's Hospital(NW) Osaka
Japan Saitama Children's Medical Center(NW) Saitama
Japan Jichi Children's Medical Center Tochigi Saitama-shi Saitama-ken
Japan Hokkaido University Hospital Sapporo Hokkaido
Japan Shizuoka Institute of Epilepsy and Neurological Disorders Shizuoka Shizuoka Prefecture
Japan Osaka University Hospital Suita
Japan National Center Hospital, NCNP Tokyo
Japan Tokyo Women's Medical University Hospital Tokyo Kawadacho
Japan Tottori University Hospital Tottori
Japan Tokyo Women's Medical University Yachiyo Medical Center Yachiyo Owada Shinden
Japan Osaka University Hospital Yamadaoka
Japan Kanagawa Children's Medical Center(NW) Yokohama

Sponsors (1)

Lead Sponsor Collaborator
Shire

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Response Rate Response rate was defined as the percentage of participants with therapeutic success. Therapeutic success was defined as the cessation of visible seizure activity within 10 minutes with a sustained absence of visible seizure activity for 30 minutes following a single dose of MHOS/SHP615 without the need for additional rescue medication. From start of study drug administration up to 30 minutes post-dose
Secondary Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours Percentage of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported. From start of study drug administration up to 1, 4 and 6 hours post-dose
Secondary Number of Participants With Time to Resolution of Seizures (Convulsions) Time to resolution of seizures (convulsions) was calculated as time from IP administration to the end of the initial seizure or administration of rescue anti-convulsant medication, whichever occurs first. Initial seizure referred to the seizure that triggered the use of the IP. Number of participants with time to resolution of seizures (convulsions) from the administration of SHP615 were reported. From start of study drug administration up to follow-up (Day 8)
Secondary Number of Participants With Time to Recovery of Consciousness Time to recovery of consciousness (in minutes) was calculated only for participants who lost consciousness pre-dose at time from investigational product administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first. Number of participants with time to recovery of consciousness were reported. From start of study drug administration up to follow-up (Day 8)
Secondary Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) Percentage of participants who required additional anticonvulsant medication for ongoing SE, 10 minutes after a single dose of SHP615 were reported. 10 minutes post-dose
Secondary Percentage of Participants Who Failed to Respond to the Treatment With SHP615 Treatment failure/non-responder was defined as participants with continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline, for 10 mins or more after a single dose of the IP. 10 minutes post-dose
Secondary Concentration of SHP615 in Plasma at 10 Minutes (C10) Concentration of SHP615 in plasma at 10 minutes were reported. 10 minutes post-dose
Secondary Maximum Plasma Concentration (Cmax) of SHP615 Cmax of SHP615 in plasma were reported. 1, 3, 6 hours post-dose
Secondary Area Under the Concentration-time Curve From Time Zero to 10 Minutes (AUC0-10) of SHP615 in Plasma AUC0-10 of SHP615 in plasma were reported. Here "min ng/mL" was minutes nanogram per milliliter. Pre-dose, 10 minutes post-dose
Secondary Area Under the Concentration-time Curve From Time Zero to 60 Minutes (AUC0-60) of SHP615 in Plasma AUC0-60 of SHP615 in plasma were reported. Pre-dose, 60 minutes post-dose
Secondary Area Under the Concentration-time Curve From Time Zero to 180 Minutes (AUC0-180) of SHP615 in Plasma AUC0-180 of SHP615 in plasma were reported. Pre-dose, 180 minutes post-dose
Secondary Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of SHP615 in Plasma AUC(0-infinity) of SHP615 in plasma were reported. Pre-dose, 1, 3, and 6 hours post-dose
Secondary Time at Maximum Concentration (Tmax) of SHP615 in Plasma Tmax of SHP615 in plasma were reported. 1, 3, and 6 hours post-dose
Secondary Elimination Half-life (T1/2) of SHP615 in Plasma T1/2 of SHP615 in plasma were reported. 1, 3, and 6 hours post-dose
Secondary Number of Participants With Respiratory Depression Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to < 92 percent (%) measured at 10, 30 minutes, and 4, 6, and 24 hours post-dose (i.e, < 92 % on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]) ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation). Number of participants with respiratory depression were reported. From start of study drug administration up to follow-up (Day 8)
Secondary Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs) TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with aspiration pneumonia identified as TEAEs were reported. From start of study drug administration up to follow-up (Day 8)
Secondary Change From Baseline in Riker Sedation-Agitation Scale at 24 Hours Post-dose Sedation-Agitation was assessed, using the "Riker Sedation-Agitation Scale" (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable. Change from baseline in riker sedation-agition scale at 24 hours post-dose were reported. Baseline, 24 hours post-dose
Secondary Number of Participants With Treatment-Emergent Adverse Events (TEAEs) An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP. Number of participants with TEAEs were reported. From start of study drug administration up to follow-up (Day 8)
Secondary Change From Baseline in Oxygen Saturation Percentage at 24 Hours Post-dose Oxygen saturation at baseline was measured and recorded on room air. The investigator had recorded the oxygen saturation, oxygen delivery system and amount of oxygen administered during the study. Change from baseline in oxygen saturation percentage at 24 hours post-dose were reported. Baseline, 24 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Active, not recruiting NCT02284126 - Topical Vancomycin for Neurosurgery Wound Prophylaxis Phase 3
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT00739518 - Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams N/A
Recruiting NCT03678194 - Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application N/A
Recruiting NCT04698421 - Collection of Biological Samples From Patients With Rare Neurological Diseases
Recruiting NCT06111898 - Neuro-biomechanical Determinants for Motor Behavior in High-risk Infants